São Paulo, August 2020 – Eurofarma, the Brazilian pharmaceutical company that invests the most in innovation in the country, is featured in the Top 100 Open Corps 2020 ranking. Organized by the 100 Open Startups platform, the survey identifies which companies are leaders in open innovation and assesses the engagement of large companies in the Brazilian innovation ecosystem.
According to the survey, in the last 12 months, 1,635 companies have entered into partnerships with startups, a figure that represents a twentyfold growth in five years of data presented by the movement. The Top 100 Open Corps ranking, which has been published for two years, is included in the 100 Open Startups ranking, which has been analyzed since 2016, is a benchmark for the market, and uses objective criteria linked to the business relationships developed between startups and large companies.
Eurofarma invests in open innovation through the Synapsis program, created in 2018 with the aim of fostering entrepreneurship and seeking innovative solutions that would help in the company’s daily operations. During the first year, twelve companies were accelerated and nine pilot projects were conducted, resulting in three companies being hired. Last year, eight scale-ups were selected and eight pilot projects conducted, resulting in two companies being hired. In 2020, Eurofarma Synapsis partnered with Endeavor to promote the Scale-up B2B program, for which more than 300 companies from various areas signed up. Of these, 16 were selected and are currently in the mentoring stage.
The Top 100 Open Corps ranking was officially announced during the August special edition of the XII Open Innovation Week (Oiweek). Brazil’s largest open innovation event, Oiweek takes place on August 26-28 and brought to light another interesting fact: 40% of the country’s top 100 open innovation programs are led by women.
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.